Registry of Pulmonary Embolism Outcomes in Poland
Polish Multicenter Pulmonary Embolism Response Teams Outcomes Registry
This study is collecting information about how patients with acute pulmonary embolism are treated and what happens to them in Poland to improve care for everyone with this condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Poznan University of Medical Sciences Academic / other |
| Locations | 1 site (Poznan, GreaterPoland) |
| Trial ID | NCT04879069 on ClinicalTrials.gov |
What this trial studies
This registry aims to document the current practices and outcomes for patients with acute pulmonary embolism (PE) treated by Pulmonary Embolism Response Teams (PERTs) across Poland. It collects data on patient clinical status, co-morbidities, treatment modalities, and outcomes, including complications such as respiratory failure and major bleeding. The study is observational and does not influence the standard diagnosis and treatment of patients. The data is managed by the Poznan University of Medical Sciences, ensuring a comprehensive overview of PE management in the region.
Who should consider this trial
Good fit: Ideal candidates include patients with confirmed pulmonary embolism experiencing symptoms for 14 days or less, particularly those with high-risk features or right ventricle dysfunction.
Not a fit: Patients who refuse to sign the informed consent form will not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could enhance understanding of PE management and improve patient outcomes through better-informed treatment strategies.
How similar studies have performed: While the PERT concept has been implemented in various settings, this specific registry approach is novel in Poland and aims to gather localized data.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. PE confirmed by computed tomography pulmonary angiography. 2. PE symptoms duration ≤ 14 days. 3. High-risk PE with hemodynamic instability (one of): * cardiac arrest * obstructive shock * persistent hypotension. 4. Intermediate-high risk PE patients with right ventricle dysfunction confirmed by imaging studies and elevated troponin level. Exclusion Criteria: 1\. Refusal to sign the informed consent form.
Where this trial is running
Poznan, GreaterPoland
- Poznan University of Medical Sciences — Poznan, GreaterPoland, Poland (Recruiting)
Study contacts
- Principal investigator: Aleksander Araszkiewicz, Prof. — Poznan University of Medical Sciences
- Study coordinator: Aleksander Araszkiewicz
- Email: aaraszkiewicz@ump.edu.pl
- Phone: 8549146
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.